- Home
- Publications
- Publication Search
- Publication Details
Title
The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 11, Pages 2342
Publisher
MDPI AG
Online
2020-10-23
DOI
10.3390/cells9112342
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration resistant prostate cancer.
- (2020) M.P. Kolinsky et al. ANNALS OF ONCOLOGY
- A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer
- (2020) Deaglan J. McHugh et al. Clinical Genitourinary Cancer
- Influence of Diet and Nutrition on Prostate Cancer
- (2020) Makoto Matsushita et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Results of a phase Ib trial of encapsulated rapamycin in prostate cancer patients under active surveillance to prevent progression.
- (2020) Phillip M. Kemp Bohan et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN)
- (2020) Tamara Jamaspishvili et al. JNCI-Journal of the National Cancer Institute
- A case report of multiple primary prostate tumors with differential drug sensitivity
- (2020) Scott Wilkinson et al. Nature Communications
- The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
- (2020) Geert J.L.H. van Leenders et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Gene editing and CRISPR in the clinic: current and future perspectives
- (2020) Matthew P. Hirakawa et al. BIOSCIENCE REPORTS
- CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
- (2020) Cheng Hu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
- (2020) Hussein Abdul-Hassan Tawbi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment
- (2020) Shahin Aghamiri et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance
- (2020) Mio Yamaguchi et al. Breast Cancer
- Cost-effectiveness of a Dual (Immunohistochemistry and Fluorescence In Situ Hybridization) HER2/neu Testing Strategy on Invasive Breast Cancers
- (2020) Nosaibah Hariri et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Targeting Rac and Cdc42 GEFs in Metastatic Cancer
- (2020) Maria del Mar Maldonado et al. Frontiers in Cell and Developmental Biology
- The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
- (2020) Boris Y. Shorning et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy
- (2020) Fabiana Conciatori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inhibition of Rac1 reverses enzalutamide resistance in castration‑resistant prostate cancer
- (2020) Xiaoliang Chen et al. Oncology Letters
- Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
- (2020) Timothy A. Yap et al. Cancer Discovery
- Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
- (2020) Federico La Manna et al. Frontiers in Oncology
- Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
- (2020) Nicholas C Turner et al. LANCET ONCOLOGY
- High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts
- (2020) Stephanie A. Harmon et al. MODERN PATHOLOGY
- PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?
- (2019) Chiara Bazzichetto et al. Cancers
- MicroRNA-21 and microRNA-30c as diagnostic biomarkers for prostate cancer: a meta-analysis
- (2019) Hongxing Zhou et al. Cancer Management and Research
- PKCζ facilitates lymphatic metastatic spread of prostate cancer cells in a mice xenograft model
- (2019) Guangxiang Zang et al. ONCOGENE
- Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
- (2019) Junfei Zhao et al. NATURE MEDICINE
- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
- (2019) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review)
- (2019) Diana Rodr�guez‑Rodr�guez et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Inhibition of Cdc42–intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth
- (2019) Byron J. Aguilar et al. CANCER BIOLOGY & THERAPY
- Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
- (2019) Vadim S. Koshkin et al. INVESTIGATIONAL NEW DRUGS
- Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.
- (2019) Christopher Sweeney et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells
- (2019) Thiago Vidotto et al. PROSTATE
- Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
- (2019) Eda K. Holl et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
- (2019) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis
- (2019) R. Liu et al. Clinical & Translational Oncology
- Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma
- (2019) Weiyi Peng et al. CLINICAL CANCER RESEARCH
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting mTOR for cancer therapy
- (2019) Hui Hua et al. Journal of Hematology & Oncology
- MicroRNA‐498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN
- (2019) Xiu‐Mei Duan et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy
- (2019) Daniel J. Canter et al. PROSTATE CANCER AND PROSTATIC DISEASES
- The PTEN–PI3K Axis in Cancer
- (2019) Papa et al. Biomolecules
- Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
- (2019) Hannah Tovell et al. ACS Chemical Biology
- Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer
- (2019) Daniel J. George et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma
- (2019) Phuong Nguyen et al. Frontiers in Oncology
- Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer
- (2019) Santosh Gupta et al. GENES CHROMOSOMES & CANCER
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
- (2019) Chenjing Zhu et al. Molecular Cancer
- DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals
- (2019) Xiaoyu Chen et al. ONCOGENE
- Tumor microenvironment components: Allies of cancer progression
- (2019) Pablo Igor Ribeiro Franco et al. PATHOLOGY RESEARCH AND PRACTICE
- Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer
- (2019) Kristina Totland Carm et al. Scientific Reports
- Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
- (2019) Geny Piro et al. Cancers
- Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis
- (2019) Jian Sun et al. BMC Medical Genetics
- High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling
- (2018) Takuji Hayashi et al. CLINICAL CANCER RESEARCH
- A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease
- (2018) Stephen K. Van Den Eeden et al. EUROPEAN UROLOGY
- A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
- (2018) Carol Aghajanian et al. INVESTIGATIONAL NEW DRUGS
- A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
- (2018) Laura Graham et al. INVESTIGATIONAL NEW DRUGS
- SGK1 inhibition-induced autophagy impairs prostate cancer metastasis by reversing EMT
- (2018) Weiwei Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- MicroRNA-guided gene expression in prostate cancer: Literature and database overview
- (2018) Olga E. Bryzgunova et al. JOURNAL OF GENE MEDICINE
- Targeting Gas6/TAM in cancer cells and tumor microenvironment
- (2018) Guiling Wu et al. Molecular Cancer
- Targeting the tumour stroma to improve cancer therapy
- (2018) Kenneth C. Valkenburg et al. Nature Reviews Clinical Oncology
- Clinical implications of PTEN loss in prostate cancer
- (2018) Tamara Jamaspishvili et al. Nature Reviews Urology
- COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer
- (2018) Rachana Garg et al. ONCOGENE
- AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
- (2018) Qiang Zuo et al. ONCOGENE
- The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1
- (2018) Boyi Zhang et al. Nature Communications
- Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
- (2018) Helen B. Pearson et al. Cancer Discovery
- Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
- (2018) W. Y. Mansour et al. Scientific Reports
- Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era
- (2018) Juan M. Arriaga et al. Cold Spring Harbor Perspectives in Medicine
- Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer
- (2018) Thiago Vidotto et al. Molecular Cytogenetics
- Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
- (2018) Maria Riedel et al. Jove-Journal of Visualized Experiments
- Engineering PTEN-L for Cell-Mediated Delivery
- (2018) Sylvie J. Lavictoire et al. Molecular Therapy-Methods & Clinical Development
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification
- (2018) Tarek A. Bismar et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).
- (2018) Simon Pacey et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-Targeting the Cell Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ inhibitor BAY1082439
- (2018) Yongkang Zou et al. MOLECULAR CANCER THERAPEUTICS
- IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
- (2018) Arianna Calcinotto et al. NATURE
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
- (2018) Benjamin D. Hopkins et al. NATURE
- The Effect of Nanoparticle Mediated Phosphatase and Tensin Homologue on Chromosome Ten on Prostate Cancer
- (2018) Yunfang Sun et al. Journal of Biomaterials and Tissue Engineering
- Antisense oligonucleotides against miR-21 inhibit the growth and metastasis of colorectal carcinoma via DUSP8 pathway
- (2018) Tao Ding et al. Molecular Therapy-Nucleic Acids
- miR-93 Promotes the Growth and Invasion of Prostate Cancer by Upregulating Its Target Genes TGFBR2, ITGB8, and LATS2
- (2018) Jia-Ji Liu et al. Molecular Therapy-Oncolytics
- Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA
- (2018) Mohammad Ariful Islam et al. Nature Biomedical Engineering
- PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome
- (2018) Antal Tapodi et al. BIOCHEMICAL PHARMACOLOGY
- Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer
- (2018) Pedro C. Barata et al. INVESTIGATIONAL NEW DRUGS
- AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer
- (2018) Haley D. Axelrod et al. MOLECULAR CANCER RESEARCH
- PTEN status assessment in the Johns Hopkins active surveillance cohort
- (2018) Jeffrey J. Tosoian et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Biomarkers Associated with Tumor Heterogeneity in Prostate Cancer
- (2018) Jae Won Yun et al. Translational Oncology
- miR‑106a contributes to prostate carcinoma progression through PTEN
- (2018) Ji Lu et al. Oncology Letters
- Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland
- (2018) Caitlin E. Jones et al. NEOPLASIA
- Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System
- (2018) Colette Moses et al. Molecular Therapy-Nucleic Acids
- Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
- (2018) Johann S. de Bono et al. CLINICAL CANCER RESEARCH
- Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
- (2017) Christophe Massard et al. EUROPEAN JOURNAL OF CANCER
- Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
- (2017) Andrew J. Armstrong et al. EUROPEAN JOURNAL OF CANCER
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
- (2017) Vivek Narayan et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer
- (2017) Simon J. Crabb et al. INVESTIGATIONAL NEW DRUGS
- Expression of PTEN-long mediated by CRISPR/Cas9 can repress U87 cell proliferation
- (2017) Na Fang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease
- (2017) Daniel E. Spratt et al. JOURNAL OF CLINICAL ONCOLOGY
- PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy
- (2017) Liana B. Guedes et al. JOURNAL OF UROLOGY
- Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
- (2017) Nico van Zandwijk et al. LANCET ONCOLOGY
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
- (2017) Xiao X. Wei et al. ONCOLOGIST
- BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma
- (2017) Ping Zhao et al. PLoS One
- LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics
- (2017) Holly M. Nguyen et al. PROSTATE
- Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells
- (2017) Chenchen He et al. PROSTATE
- PKCζ in prostate cancer cells represses the recruitment and M2 polarization of macrophages in the prostate cancer microenvironment
- (2017) Hui-hui Fan et al. TUMOR BIOLOGY
- miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study
- (2017) Yu Yang et al. Asian Pacific Journal of Tropical Medicine
- PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer
- (2017) Darren J. Wozniak et al. Nature Communications
- PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort
- (2017) Tamara L. Lotan et al. Oncotarget
- Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer
- (2017) Jian-Zhong Lin et al. Oncotarget
- Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia
- (2017) Hongqi Liu et al. Cell Reports
- Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway
- (2017) Rachana Garg et al. Cell Reports
- Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance
- (2017) Christine Levesque et al. Cold Spring Harbor Perspectives in Medicine
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- Genetic Deletion of Akt3 Induces an Endophenotype Reminiscent of Psychiatric Manifestations in Mice
- (2017) Yan Bergeron et al. Frontiers in Molecular Neuroscience
- AR Signaling and the PI3K Pathway in Prostate Cancer
- (2017) Megan Crumbaker et al. Cancers
- A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
- (2016) Helen Chow et al. CANCER
- Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms
- (2016) Qi Wang et al. CANCER CELL
- PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
- (2016) Pau Castel et al. CANCER CELL
- Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
- (2016) Kenji Tamura et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The hVps34‐SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth
- (2016) Ruzica Bago et al. EMBO JOURNAL
- Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland
- (2016) Stefano Annunziato et al. GENES & DEVELOPMENT
- Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes
- (2016) Dong Wang et al. GYNECOLOGIC ONCOLOGY
- Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
- (2016) Muhammad S. Beg et al. INVESTIGATIONAL NEW DRUGS
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
- (2016) Claire L Vale et al. LANCET ONCOLOGY
- Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH
- (2016) Tamara L Lotan et al. MODERN PATHOLOGY
- PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance
- (2016) Bruce J Trock et al. MODERN PATHOLOGY
- Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations
- (2016) D. Bianchi-Frias et al. MOLECULAR CANCER RESEARCH
- Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/ BRAF -Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor
- (2016) Hélène Bonnevaux et al. MOLECULAR CANCER THERAPEUTICS
- Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
- (2016) Alexis C. Komor et al. NATURE
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
- (2016) Freddie C. Hamdy et al. NEW ENGLAND JOURNAL OF MEDICINE
- BEZ235: When Promising Science Meets Clinical Reality
- (2016) G. Pongas et al. ONCOLOGIST
- Repair Pathway Choices and Consequences at the Double-Strand Break
- (2016) Raphael Ceccaldi et al. TRENDS IN CELL BIOLOGY
- In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading
- (2016) C. G. Picanço-Albuquerque et al. VIRCHOWS ARCHIV
- Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer
- (2016) Glen Reid et al. Epigenomics
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- Hyperinsulinemia enhances interleukin-17-induced inflammation to promote prostate cancer development in obese mice through inhibiting glycogen synthase kinase 3-mediated phosphorylation and degradation of interleukin-17 receptor
- (2016) Sen Liu et al. Oncotarget
- Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome
- (2016) Shuai Zhen et al. Oncotarget
- Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
- (2016) Marco A. De Velasco et al. Oncotarget
- PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy
- (2016) Chris W.D. Armstrong et al. Oncotarget
- Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer
- (2016) Hannah Nip et al. Oncotarget
- Intracellular delivery of the PTEN protein using cationic lipidoids for cancer therapy
- (2016) Sarah A. Altınoğlu et al. Biomaterials Science
- microRNA Therapeutics in Cancer — An Emerging Concept
- (2016) Maitri Y. Shah et al. EBioMedicine
- BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
- (2016) Maria-Carmela Speranza et al. Scientific Reports
- Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer
- (2015) Swati Dhar et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
- (2015) Elizabeth A Punnoose et al. BRITISH JOURNAL OF CANCER
- Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications
- (2015) Dana E. Rathkopf et al. CANCER
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
- (2015) Sarit Schwartz et al. CANCER CELL
- CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy
- (2015) J. Escamilla et al. CANCER RESEARCH
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
- (2015) W. Mo et al. CLINICAL CANCER RESEARCH
- A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients
- (2015) Y. Guo et al. CLINICAL CANCER RESEARCH
- TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients
- (2015) D. M. S. Hossain et al. CLINICAL CANCER RESEARCH
- A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
- (2015) S. Gupta et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
- (2015) Kevin D. Courtney et al. Clinical Genitourinary Cancer
- PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
- (2015) Roberta Ferraldeschi et al. EUROPEAN UROLOGY
- Adenovirus-Mediated Somatic Genome Editing ofPtenby CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses
- (2015) Dan Wang et al. HUMAN GENE THERAPY
- Trends in Management for Patients With Localized Prostate Cancer, 1990-2013
- (2015) Matthew R. Cooperberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Study of PTEN subcellular localization
- (2015) Angela Bononi et al. METHODS
- PTEN: A yin-yang master regulator protein in health and disease
- (2015) Rafael Pulido METHODS
- PKC Is an Essential Mediator of Prostate Cancer Bone Metastasis
- (2015) A. Gutierrez-Uzquiza et al. MOLECULAR CANCER RESEARCH
- Abstract A123: Preclinical evaluation of dual mTOR inhibitor, AZD2014, in prostate cancer
- (2015) Chiranjeevi Sandi et al. MOLECULAR CANCER THERAPEUTICS
- Abstract B59: Dual mTOR kinase inhibitor reverses rapamycin resistance in prostate cancer cells
- (2015) Yao Dai et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Exosome-mediated Delivery of the Intrinsic C-terminus Domain of PTEN Protects It From Proteasomal Degradation and Ablates Tumorigenesis
- (2015) Syed Feroj Ahmed et al. MOLECULAR THERAPY
- MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation
- (2015) Remi-Martin Laberge et al. NATURE CELL BIOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice
- (2015) Ruibao Chen et al. PROSTATE
- PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion
- (2015) Sarah M. Mense et al. Science Signaling
- Microenvironmental regulation of therapeutic response in cancer
- (2015) Florian Klemm et al. TRENDS IN CELL BIOLOGY
- Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models
- (2015) Giovanni Luca Gravina et al. TUMOR BIOLOGY
- Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
- (2015) Ulka Vaishampayan et al. UROLOGY
- A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis
- (2015) Haluk Yuzugullu et al. Nature Communications
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer
- (2015) Swati Dhar et al. Oncotarget
- AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2
- (2015) Hui-Ping Lin et al. Oncotarget
- Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src Activation
- (2015) Amita Daverey et al. Scientific Reports
- PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion
- (2015) Sarah M. Mense et al. Science Signaling
- Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors
- (2015) Diletta Di Mitri et al. OncoImmunology
- Relevance and Therapeutic Possibility of PTEN-Long in Renal Cell Carcinoma
- (2015) Hui Wang et al. PLoS One
- Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells
- (2015) Pamela J. Maxwell et al. Oncotarget
- GAS6/AXL Axis Regulates Prostate Cancer Invasion, Proliferation, and Survival in the Bone Marrow Niche
- (2015) Yusuke Shiozawa et al. NEOPLASIA
- Cooperation between Stat3 and Akt Signaling Leads to Prostate Tumor Development in Transgenic Mice
- (2015) Jorge M. Blando et al. NEOPLASIA
- The Brain Microenvironment Preferentially Enhances the Radioresistance of CD133+ Glioblastoma Stem-like Cells
- (2015) Muhammad Jamal et al. NEOPLASIA
- Metabolic Reprogramming of Stromal Fibroblasts through p62-mTORC1 Signaling Promotes Inflammation and Tumorigenesis
- (2014) Tania Valencia et al. CANCER CELL
- Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors
- (2014) Monica Mita et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial
- (2014) B. Gurel et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Therapeutic Targeting of Cancers with Loss of PTEN Function
- (2014) Lloye Dillon et al. CURRENT DRUG TARGETS
- PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer
- (2014) Prabhakar Mithal et al. INTERNATIONAL JOURNAL OF UROLOGY
- Classes of phosphoinositide 3-kinases at a glance
- (2014) S. Jean et al. JOURNAL OF CELL SCIENCE
- PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy
- (2014) Tamara L Lotan et al. MODERN PATHOLOGY
- Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
- (2014) A. J. Garcia et al. MOLECULAR AND CELLULAR BIOLOGY
- Senescent stroma promotes prostate cancer progression: The role of miR-210
- (2014) Maria Letizia Taddei et al. Molecular Oncology
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression
- (2014) Janna K Mouw et al. NATURE MEDICINE
- Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
- (2014) Samir Mitragotri et al. NATURE REVIEWS DRUG DISCOVERY
- Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors
- (2014) Weisheng Zhang et al. Translational Oncology
- PTEN function: the long and the short of it
- (2014) Benjamin D. Hopkins et al. TRENDS IN BIOCHEMICAL SCIENCES
- PTEN-Deficient Tumors Depend on AKT2 for Maintenance and Survival
- (2014) Y. R. Chin et al. Cancer Discovery
- Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition
- (2014) E. Gonzalez-Billalabeitia et al. Cancer Discovery
- Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity
- (2014) Alberto Toso et al. Cell Reports
- Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities
- (2014) Erin D Lew et al. eLife
- Gas6 induces cancer cell migration and epithelial–mesenchymal transition through upregulation of MAPK and Slug
- (2013) Yunhee Lee et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
- (2013) Eeva M. Sommer et al. BIOCHEMICAL JOURNAL
- A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
- (2013) K Kruczek et al. BRITISH JOURNAL OF CANCER
- Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer
- (2013) K. A. Leinonen et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- mTOR kinase inhibitors as potential cancer therapeutic drugs
- (2013) Shi-Yong Sun CANCER LETTERS
- RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
- (2013) Ralph Fritsch et al. CELL
- Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer
- (2013) Christine M. Barnett et al. CLINICAL CANCER RESEARCH
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
- (2013) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
- (2013) Andrew J. Armstrong et al. Clinical Genitourinary Cancer
- Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
- (2013) Arnoud J. Templeton et al. EUROPEAN UROLOGY
- Akt and mTORC1 Have Different Roles During Liver Tumorigenesis in Mice
- (2013) Heidi L. Kenerson et al. GASTROENTEROLOGY
- Silencing of miR-21 by locked nucleic acid–lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death
- (2013) A. Griveau et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy
- (2013) Prerna Malaney et al. Molecular BioSystems
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis
- (2013) H. K. Bid et al. MOLECULAR CANCER THERAPEUTICS
- Protein kinase C and cancer: what we know and what we do not
- (2013) R Garg et al. ONCOGENE
- PTEN functions as a melanoma tumor suppressor by promoting host immune response
- (2013) Y Dong et al. ONCOGENE
- A Rac1/Cdc42 GTPase-Specific Small Molecule Inhibitor Suppresses Growth of Primary Human Prostate Cancer Xenografts and Prolongs Survival in Mice
- (2013) Karin Zins et al. PLoS One
- c-Myc phosphorylation by PKC represses prostate tumorigenesis
- (2013) J. Y. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Small molecule targeting Cdc42–intersectin interaction disrupts Golgi organization and suppresses cell motility
- (2013) Amy Friesland et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin
- (2013) Oh-Joon Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival
- (2013) B. D. Hopkins et al. SCIENCE
- Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress
- (2013) C. Bassi et al. SCIENCE
- The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia
- (2013) Kenichi Hirai et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Base Excision Repair
- (2013) H. E. Krokan et al. Cold Spring Harbor Perspectives in Biology
- p110δ PI3 kinase pathway: emerging roles in cancer
- (2013) Niki Tzenaki et al. Frontiers in Oncology
- Genomic Rearrangements of PTEN in Prostate Cancer
- (2013) Sopheap Phin et al. Frontiers in Oncology
- Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
- (2012) Mari Nakabayashi et al. BJU INTERNATIONAL
- Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy
- (2012) Gaetano Zafarana et al. CANCER
- Adult Murine Prostate Basal and Luminal Cells Are Self-Sustained Lineages that Can Both Serve as Targets for Prostate Cancer Initiation
- (2012) Nahyun Choi et al. CANCER CELL
- PTEN in DNA damage repair
- (2012) Mei Ming et al. CANCER LETTERS
- B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer
- (2012) J. Wang et al. CANCER RESEARCH
- Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells
- (2012) D. J. Mulholland et al. CANCER RESEARCH
- Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
- (2012) T. Sangai et al. CLINICAL CANCER RESEARCH
- Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
- (2012) Himisha Beltran et al. EUROPEAN UROLOGY
- Potentiation of Inflammatory CXCL8 Signalling Sustains Cell Survival in PTEN-deficient Prostate Carcinoma
- (2012) Pamela J. Maxwell et al. EUROPEAN UROLOGY
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Prodrug Strategy for PSMA-Targeted Delivery of TGX-221 to Prostate Cancer Cells
- (2012) Yunqi Zhao et al. MOLECULAR PHARMACEUTICS
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
- (2012) Christopher E Barbieri et al. NATURE GENETICS
- Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
- (2012) Yu Sun et al. NATURE MEDICINE
- Homologous recombination and its regulation
- (2012) L. Krejci et al. NUCLEIC ACIDS RESEARCH
- The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target
- (2012) J D Paccez et al. ONCOGENE
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery
- (2012) J. Predina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer
- (2012) Ziqing Wu et al. PROSTATE
- The Tumor Suppressor PTEN Is Exported in Exosomes and Has Phosphatase Activity in Recipient Cells
- (2012) U. Putz et al. Science Signaling
- Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells
- (2012) P Kharaziha et al. Cell Death & Disease
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
- (2012) Jing Ni et al. Cancer Discovery
- Reduction ofPtendose leads to neoplastic development in multiple organs ofPtenshRNAmice
- (2011) Hong Shen-Li et al. CANCER BIOLOGY & THERAPY
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
- (2011) David J. Mulholland et al. CANCER CELL
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- PTEN Positively Regulates UVB-Induced DNA Damage Repair
- (2011) M. Ming et al. CANCER RESEARCH
- Rac signaling in breast cancer: A tale of GEFs and GAPs
- (2011) Eva Wertheimer et al. CELLULAR SIGNALLING
- PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
- (2011) T. L. Lotan et al. CLINICAL CANCER RESEARCH
- PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
- (2011) M. Fraser et al. CLINICAL CANCER RESEARCH
- Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
- (2011) T. Shree et al. GENES & DEVELOPMENT
- PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications
- (2011) Maisa Yoshimoto et al. GENES CHROMOSOMES & CANCER
- Prostate cancer and inflammation: the evidence
- (2011) Karen S Sfanos et al. HISTOPATHOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Development of a Peptide–Drug Conjugate for Prostate Cancer Therapy
- (2011) Wanyi Tai et al. MOLECULAR PHARMACEUTICS
- The effect Akt2 deletion on tumor development in Pten+/− mice
- (2011) P-Z Xu et al. ONCOGENE
- Non-genomic loss of PTEN function in cancer: not in my genes
- (2011) Nick R. Leslie et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells
- (2011) Lizhi He et al. Nature Communications
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
- (2010) K. A. Edgar et al. CANCER RESEARCH
- A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
- (2010) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- Phosphoinositide 3-Kinase Pathway Activation in Phosphate and Tensin Homolog (PTEN)-deficient Prostate Cancer Cells Is Independent of Receptor Tyrosine Kinases and Mediated by the p110β and p110δ Catalytic Subunits
- (2010) Xinnong Jiang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Depletion ofDNMT3ASuppressed Cell Proliferation and RestoredPTENin Hepatocellular Carcinoma Cell
- (2010) Zhujiang Zhao et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- Subtle variations in Pten dose determine cancer susceptibility
- (2010) Andrea Alimonti et al. NATURE GENETICS
- Targeting microRNAs in cancer: rationale, strategies and challenges
- (2010) Ramiro Garzon et al. NATURE REVIEWS DRUG DISCOVERY
- Identification of the miR-106b 25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation
- (2010) L. Poliseno et al. Science Signaling
- PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth
- (2009) Jorge Blando et al. AMERICAN JOURNAL OF PATHOLOGY
- PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol
- (2009) Arpad Szanto et al. BIOCHEMICAL PHARMACOLOGY
- A complex interplay between Akt, TSC2 and the two mTOR complexes: Figure 1
- (2009) Jingxiang Huang et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
- (2009) Wenqing Qi et al. BMC CANCER
- mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
- (2009) David A. Guertin et al. CANCER CELL
- mTOR and cancer: many loops in one pathway
- (2009) Alejo Efeyan et al. CURRENT OPINION IN CELL BIOLOGY
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer
- (2009) Festuccia INTERNATIONAL JOURNAL OF ONCOLOGY
- Pten in stromal fibroblasts suppresses mammary epithelial tumours
- (2009) Anthony J. Trimboli et al. NATURE
- Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis
- (2009) J Qin et al. ONCOGENE
- PTEN and the PI3-Kinase Pathway in Cancer
- (2008) Nader Chalhoub et al. Annual Review of Pathology-Mechanisms of Disease
- mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
- (2008) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Senescence-Associated Exosome Release from Human Prostate Cancer Cells
- (2008) B. D. Lehmann et al. CANCER RESEARCH
- Development of a Small-Molecule Serum- and Glucocorticoid-Regulated Kinase-1 Antagonist and Its Evaluation as a Prostate Cancer Therapeutic
- (2008) A. B. Sherk et al. CANCER RESEARCH
- Inhibition of α-mannosidaseMan2c1gene expression suppresses growth of esophageal carcinoma cells through mitotic arrest and apoptosis
- (2008) Yun Tian et al. CANCER SCIENCE
- Homologous recombination in DNA repair and DNA damage tolerance
- (2008) Xuan Li et al. CELL RESEARCH
- Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer
- (2008) Robert J. Amato et al. Clinical Genitourinary Cancer
- Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
- (2008) Tsuneo Ikenoue et al. EMBO JOURNAL
- DNA mismatch repair: Molecular mechanism, cancer, and ageing
- (2008) Peggy Hsieh et al. MECHANISMS OF AGEING AND DEVELOPMENT
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
- (2008) Shidong Jia et al. NATURE
- PI3K/Akt: getting it right matters
- (2008) T F Franke ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search